Induced pluripotent stem cell-derived endothelial progenitor cells attenuate ischemic acute kidney injury and cardiac dysfunction

Wen-Ching Shen1,2, Yu-Hsiang Chou2,3,4, Hsiang-Po Huang5,6, Jenn-Feng Sheen7, Shih-Chieh Hung1,8,9 and Hsin-Fu Chen5,10*

Abstract

Background: Renal ischemia–reperfusion (I/R) injury is a major cause of acute kidney injury (AKI), which is associated with high morbidity and mortality. AKI is a serious and costly medical condition. Effective therapy for AKI is an unmet clinical need, and molecular mechanisms underlying the interactions between an injured kidney and distant organs remain unclear. Therefore, novel therapeutic strategies should be developed.

Methods: We directed the differentiation of human induced pluripotent stem (iPS) cells into endothelial progenitor cells (iEPCs), which were then applied for treating mouse AKI. The mouse model of AKI was induced by I/R injury.

Results: We discovered that intravenously infused iEPCs were recruited to the injured kidney, expressed the mature endothelial cell marker CD31, and replaced injured endothelial cells. Moreover, infused iEPCs produced abundant proangiogenic proteins, which entered into circulation. In AKI mice, blood urea nitrogen and plasma creatinine levels increased 2 days after I/R injury and reduced after the infusion of iEPCs. Tubular injury, cell apoptosis, and peritubular capillary rarefaction in injured kidneys were attenuated accordingly. In the AKI mice, iEPC therapy also ameliorated apoptosis of cardiomyocytes and cardiac dysfunction, as indicated by echocardiography. The therapy also ameliorated an increase in serum brain natriuretic peptide. Regarding the relevant mechanisms, indoxyl sulfate and interleukin-1β synergistically induced apoptosis of cardiomyocytes. Systemic iEPC therapy downregulated the proapoptotic protein caspase-3 and upregulated the anti-apoptotic protein Bcl-2 in the hearts of the AKI mice, possibly through the reduction of indoxyl sulfate and interleukin-1β.

Conclusions: Therapy using human iPS cell-derived iEPCs provided a protective effect against ischemic AKI and remote cardiac dysfunction through the repair of endothelial cells and the attenuation of cardiomyocyte apoptosis.

Keywords: Acute kidney injury, Indoxyl sulfate, Cardiac dysfunction, Endothelial progenitor cells, Induced pluripotent stem cells
Background
Acute kidney injury (AKI) is a potentially devastating clinical problem [1]. Despite the availability of renal replacement therapy, AKI is associated with high mortality and morbidity [2–5]. When kidneys fail, dangerous levels of metabolites and waste products, including uremic toxins, accumulate in the body. Clinical evidence suggests that AKI is not only an indicator of illness severity but that it also leads to distant-organ injury and considerably affects mortality [6–10]. Grams et al. observed that AKI is not an isolated event and that it results in heart dysfunction through a proinflammatory mechanism involving inflammatory cytokine expression and increased oxidative stress [7]. A recent study further demonstrated that AKI may activate the production of dynamin-related protein 1 (Drp1) and may induce mitochondrial fragmentation in cardiomyocytes, thereby leading to cell apoptosis and cardiac dysfunction. Drp1 has thus become a new therapeutic target to alleviate AKI-induced cardiac dysfunction [10].

An increasing number of studies have provided evidence that cell therapy can lead to the repair of damaged kidney tissue; therapy with pluripotent stem cells has been demonstrated to lead to functional recovery in preclinical kidney models [11–13]. Induced pluripotent stem (iPS) cells can be obtained by reprogramming a broad range of adult somatic cell types to develop into embryonic stem cell-like pluripotent cells [14]. iPS cell technology represents a promising, novel strategy for the derivation of clinically applicable lineage-specific cells, such as endothelial progenitor cells (EPCs) [14–16]. Furthermore, iPS cells can be generated from cells from any part of an adult and exhibit potential for facilitating genetically matched “patient-specific” cell therapy, which would solve both ethical problems and immune system rejection [17, 18].

The enormous therapeutic potential of isolated human EPCs has been demonstrated for a wide range of ischemic tissues [19]. Many researchers believe that the therapeutic effect of these cells is mediated by their production of cytoprotective, anti-inflammatory, anti-apoptotic, and anti-fibrogenic factors as well as by their differentiation into specific cell types [20, 21]. Despite advances in adult stem cell technology, limited accessibility, limited numbers of functional cells, and cellular heterogeneity remain obstacles for drug discovery and successful application of regenerative medicine [13, 22, 23]. iPS cell therapy has led to functional recovery in animal models [24, 25]. However, therapy using iPS cells has also induced undesirable effects, including teratoma formation [13, 26]. Directing the differentiation of iPS cells into specific cell types for transplantation may be a more favorable option.

Yoo et al. induced the differentiation of human iPS cells into EPCs (iPS cell-derived EPCs, iEPCs) and confirmed the therapeutic effect of iEPC infusion in mouse models of hind limb ischemia and myocardial infarction [27]. Inspired by the aforementioned previous study, we considered whether therapy using iEPCs would result in protective effects in a mouse model of AKI induced by ischemia–reperfusion (I/R) injury. Our data revealed that iEPC therapy is a promising treatment strategy for AKI and remote cardiac dysfunction and that its protective effects are exerted through attenuation of apoptosis and inflammation.

Methods
An expanded version of the “Methods” section is available in Additional file 1 and includes details on the following: approval for human studies, patients, generation of human induced pluripotent stem cells, characterization of iPS cell-derived EPCs, culture of HL-1 cardiomyocytes, tissue preparation for pathological examinations, scoring of tubular injury, evaluation of microvessels, identification of apoptosis by TUNEL staining, cell lysate preparation and Western blot analysis, evaluation of renal function, measurement of plasma interleukin-1β, measurement of plasma brain natriuretic peptide, measurement of plasma indoxyl sulfate, measurement of circulating human cytokines, and echocardiographic analysis.

AKI model and iEPC therapy
Male (8–10 weeks) adult nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice were anesthetized using ketamine/xylazine (100/10 mg/kg, intraperitoneally) and were then subjected to right nephrectomy. Two weeks later, the left kidney was clamped for 24 min by using a nontraumatic micro-aneurysm clip (Karl Klappenecker, Tuttlingen-Nendingen, Germany) to induce an I/R injury under the homeothermic blanket system (Stoelting Co. Wood Dale, IL). In the blanket system, a rectal thermal probe and a heating pad were used to maintain the core body temperature at 37 °C. After removal of the clamp, blood flow reperfusion was confirmed visually. The mice were divided into two groups: AKI-iEPC mice and AKI-vehicle mice. In AKI-iEPC mice, 200 μL of phosphate-buffered saline (PBS) cell suspension containing 5 × 10⁵ iEPCs was infused via the tail vein 15 min after reperfusion. AKI-vehicle mice were infused with 200 μL of PBS. Sham controls underwent the same surgical procedure but without vascular occlusion. All of the animal experiments were performed in accordance with the details of the relevant guidelines and regulations and were approved by the Institutional Review Board of National Taiwan University Hospital.

Statistical analysis
Data are expressed as mean ± standard error of the mean (SEM). The data were analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA). One-way analysis of variance with post hoc analysis using Tukey’s method.
was conducted for multiple group comparisons. \( P < 0.05 \) was considered statistically significant.

**Results**

**Increased plasma levels of creatinine, indoxyl sulfate, and interleukin-1β in patients with AKI**

In the present study, 25 consecutive patients were enrolled upon receiving diagnosis of AKI. Day 2 serum level of creatinine was significantly higher in patients with AKI than in non-AKI controls (Fig. 1a). Serum levels of indoxyl sulfate (IS) and interleukin 1β (IL-1β) in each group were studied. Patients with AKI exhibited increased serum levels of IS (AKI, 18.1 ± 4.5 vs. non-AKI, 3.9 ± 0.6 \( \mu \)M; Fig. 1a, b) and IL-1β (AKI, 467 ± 50 vs. non-AKI, 97 ± 12 pg/mL; Additional file 1: Figure S2, Fig. 1c).

**Characterization of human iEPCs**

A colony-forming unit of iEPCs was defined as a central core of round cells with elongated sprouting cells at the periphery (Additional file 1: Figure S1a and b). In contrast to iPS cells, iEPCs were spindle shaped in morphology when they reached confluence, similar to the morphology of mature endothelial cells (Additional file 1: Figure S1c and d). We also confirmed that acetylated low-density lipoprotein (acLDL) was taken up by iEPCs but not by iPS cells (Additional file 1: Figure S1e and f). In addition, primitive vascular tube-like structures developed in iEPCs when they were grown in Matrigel (Additional file 1: Figure S1g and h). According to the results of immunostaining and flow cytometric analyses, both iPS cells and iEPCs expressed the stem cell marker CD133 (Additional file 1: Figure S2). However, only iEPCs expressed EPC marker kinase insert domain receptor (KDR; Additional file 1: Figure S2). CD31 and VE-cadherin, which are markers of mature endothelial cells, were also expressed in 57.6% and 53.3% of iEPCs, respectively (Additional file 1: Figure S2).

**Recruitment of iEPCs to the interstitium of AKI kidney**

To assess the therapeutic effect of iEPCs on I/R-induced AKI, we first determined whether iEPCs could be recruited to the injured kidney. Lentivirus-green florescent protein (GFP)-transduced iPS cells were differentiated into GFP-iEPCs (Fig. 2a, b, Additional file 1: Fig. 3a, b). Fifteen minutes after reperfusion of ischemic kidneys, \( 5 \times 10^5 \) GFP-iEPCs were injected via the tail vein, and the kidneys were analyzed 2 days later (Fig. 2c, d). Many GFP-iEPCs were detected in the interstitium of the kidneys (Fig. 2c). As expected, GFP-iEPCs were also identified in the lung, liver, and spleen (Fig. 2c). However, among the organs

![Fig. 1](image-url)

**Fig. 1** Increased plasma levels of creatinine and indoxyl sulfate in patients with AKI. **a** Bar chart denoting plasma creatinine levels in AKI and non-AKI patients. \( N = 25 \) per group. **b** Increased plasma levels of interleukin-1β in patients with AKI. Data are expressed as mean ± SEM. \( N = 10 \) per group. \( * P < 0.05 \) vs. non-AKI group. **c** Representative chromatogram for measurement of plasma indoxyl sulfate (IS). FU indicates fluorescence unit. **d** Bar chart representing plasma IS in AKI and non-AKI patients. Data are expressed as mean ± SEM. \( N = 6 \) per group. \( *P < 0.05 \) vs. non-AKI group.
examined, the proportion of GFP-iEPCs was highest in the kidneys (Fig. 2d). No GFP-iEPCs were observed in the heart.

**Systemic iEPC therapy reduced azotemia and systemic inflammation after AKI**

To assess the therapeutic effect of iEPCs on AKI, iEPCs or PBS vehicle was injected via the tail vein 15 min after renal I/R surgery. Systemic iPS and iEPC therapy resulted in a significant decrease in plasma levels of creatinine (0.4 ± 0.1 mg/dL) and blood urea nitrogen (BUN; 19.1 ± 2.7 mg/dL) compared with the levels in vehicle-treated mice (creatinine, 1.3 ± 0.3 mg/dL and BUN, 105 ± 15.1 mg/dL; Fig. 3a). Similar to findings reported for patients with AKI (Fig. 1), plasma levels of IL-1β and IS were higher in AKI-vehicle mice than those in sham mice on day 2 after injury (Fig. 3c–e). iPS or iEPC therapy reduced the increase in plasma IL-1β and IS levels in AKI mice, and this result was comparable to the therapies’ beneficial effect on kidney function (Fig. 3c–e).

**Systemic iEPC therapy attenuated tubular injury and peritubular capillary rarefaction after AKI**

Given that iEPCs were recruited to the injured kidney and reduced azotemia, we next studied the mechanisms underlying the therapeutic effect. iEPC therapy induced restoration of the corticomedullary junction in the AKI-vehicle kidney on day 2 after I/R injury (Additional file 1: Figure S4). iEPC therapy also attenuated marked tubular injuries, including intratubular cast, absence of nuclei, and tubular dilation, in the AKI-vehicle kidney (Fig. 4a, b). Terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL+) apoptotic cells in the AKI-vehicle kidney were also attenuated by iEPC therapy (Fig. 4c, d). Decreases in CD31+ staining revealed rarefaction of peritubular capillaries in the AKI-vehicle kidneys, and this was also improved by iEPC therapy (Fig. 4e–f).

**Recruited iEPCs repaired endothelial cells in AKI kidneys and expressed proangiogenic factors**

To further analyze the mechanism by which iEPCs maintained microvasculature in AKI kidneys, we determined whether iEPCs differentiated into endothelial cells. We found that all GFP-iEPCs were positive for human CD31 in the kidneys of AKI-iEPC mice, suggesting that iEPCs differentiated into mature endothelial cells (Fig. 4g). However, we discovered that GFP-iEPCs accounted for less than 1% of mouse CD31+ endothelial cells (data not shown). These investigations provided evidence of an extremely rare contribution of iEPCs to direct endothelial replacement, and
the marked expression of the mature endothelial cell marker CD31 in all recruited iEPCs was noted; therefore, we measured circulating angiogenesis-related proteins to determine whether paracrine mechanisms underlie systemic-iEPC-therapy-induced maintenance of microvasculature in AKI kidneys. Compared with levels in AKI-vehicle mice, plasma levels of angiopoietin-1 (Angpt1), angiopoietin-2 (Angpt2), vascular endothelial cell growth factor-C (VEGF-C), matrix metallopeptidase 9 (MMP9), fibroblast growth factor-1 (FGF1), FGF2, insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP-2, and transforming growth factor-β1 (TGF-β1) had considerably increased in AKI-iEPC mice 2 days after injection (Fig. 5, Additional file 1: Figure S5).

**Systemic iEPC therapy attenuated cardiac dysfunction after AKI**

The plasma level of brain natriuretic peptide (BNP) was significantly higher in patients on day 2 after AKI, suggesting congestion of cardiac atria (Additional file 1: Figure S6). To assess cardiac function in AKI mice, echocardiography was performed on day 2 after I/R surgery. Representative M-mode tracings indicated significant improvement of cardiac function in AKI mice after iEPC therapy (Fig. 6a). Cardiac dysfunction—as evident by decreases in cardiac output (CO), left ventricular ejection fraction (LVEF), and left ventricular fractional shortening (LVFS)—in AKI mice was attenuated after iEPC therapy (Fig. 6b–d). In AKI mice, elevated plasma levels of BNP, which contributes to cardiac dysfunction, were substantially attenuated by iEPC therapy, and this result agreed with the findings from echocardiography (Fig. 6e).

**Systemic iEPC therapy attenuated apoptosis of cardiomyocytes in AKI mice**

Following the previously described experiments, we investigated the possible mechanisms underlying the protective effect of iEPC therapy on cardiac function in AKI mice. Apoptosis of left ventricular cardiomyocytes, which was assessed using terminal dUTP nick-end labeling (TUNEL) staining, was elevated in AKI mice (Fig. 7a, b), and iEPC therapy substantially reduced the elevated apoptosis (Fig. 7a, b). Moreover, the expression of the apoptotic protein caspase 3, which was elevated in the left ventricle of AKI mice, was also inhibited by iEPC therapy (Fig. 7c). By contrast, the downregulation of anti-apoptotic protein Bcl-2 in the left ventricle of AKI mice was partially attenuated by iEPC therapy (Fig. 7d).
Indoxyl sulfate and interleukin-1β induced cardiomyocyte apoptosis synergistically

Based on the finding that IS and IL-1β increased systemically in AKI patients and mice (Fig. 1, Fig. 3c–e) and systemic iEPC therapy decreased IS and IL-1β in AKI mice, we determined whether IS or IL-1β played a role in the apoptosis of cardiomyocytes. At the concentrations (0.2 mM IS and 200 ng/mL) observed in patients with AKI, IS and IL-1β induced apoptosis of cardiomyocytes HL-1 (Fig. 8a, b). Moreover, IS and IL-1β synergistically induced cardiomyocyte apoptosis (Fig. 8a, b). Mechanistically, IS and IL-1β upregulated the proapoptotic protein Bax but downregulated the anti-apoptotic protein Bcl-2 in HL-1 cardiomyocytes (Fig. 8c, d).
Discussion

Our findings provide the first evidence that human iPS cell-derived iEPC therapy is a promising therapy that may attenuate apoptosis and thereby protect the kidneys from microvascular rarefaction and tubular decomposition induced by I/R injury. The present study also revealed that AKI-induced cardiomyocyte apoptosis and cardiac dysfunction were attenuated by this therapy.

I/R injury is the most common cause of AKI in patients [1]. Vascular and tubular changes, alongside interstitial inflammation, cause acute decreases in kidney function. AKI-induced IS and IL-1β, the expression of which was examined in this study, damage endothelial cells and cause myocardial injury, respectively [28, 29]. Despite extensive research through preclinical studies, no therapeutic interventions using iPS cell-derived iEPCs have been reported to prevent or accelerate recovery from AKI [30]. This failure in translation has led investigators to speculate that the animal models and study designs used in the relevant research do not predict clinical responses. Our pilot experiments with mice subjected to bilateral renal I/R injury frequently resulted in unequal kidney sizes, with one atrophic kidney and another hypertrophic kidney 2 weeks after injury. These results demonstrated the technical difficulty of inducing equal injuries to both kidneys in a model of bilateral I/R injury. Therefore, in the present study, we performed right nephrectomy in 8–10-week-old mice, followed by left renal I/R injury 2 weeks later. This AKI model was reliable and facilitated the objective evaluation of kidney function and renal pathology. Our data revealed that intravenous infusion of iEPCs 15 min after renal I/R surgery provided protective effects not only for kidney function but also for distant organs such as the heart. Lentiviral transduction enabled reliable fate tracing of infused iEPCs, and the results indicated that GFP-iEPCs were mainly recruited to the interstitium of the injured kidney. Recruited iEPCs preferentially lined up with mouse CD31+ endothelial cells and upregulated their own CD31, indicating the potential of infused iEPCs to replace injured endothelial cells. This finding is in line with those of previous reports that demonstrated the homing of EPCs, isolated from various tissues, into injured blood vessels [31–40]. However, direct endothelial replacement by GFP-iEPCs only accounted for extremely small number of cells.

![Fig. 5 a-i Systemic human iPS cell-derived iEPC therapy increased the plasma concentrations of angiogenesis-related proteins. Bar charts denoting the relative folds of plasma angiogenesis-related proteins—including Angpt1, Angpt2, VEGF-C, MMP 9, FGF 1, FGF 2, IGFBP-1, IGFBP-2, and TGF-β1—on day 2 after acute kidney injury (AKI). N = 3 per group. Data are expressed as mean ± SEM. *P < 0.001 AKI-iEPC vs. AKI-V group.](image)
in blood vessels. Our data further supported that iEPC therapy might preserve microvasculature by causing the expression of high levels of angiogenesis-related proteins, including Angpt1, Angpt2, VEGF-C, MMP9, FGF1, FGF2, IGFBP-1, IGFBP-2, and TGF-β. This finding was in line with evidence that EPCs release potent proangiogenic growth factors [41]. Proangiogenic growth factors appear to be produced not only by EPCs but also by hematopoietic stem/progenitor cells and bone-marrow-derived mesenchymal stem cells [11, 42]. In this study, we did not gain insight into the role of each angiogenesis-related protein expressed in AKI-iEPC mice. However, the proangiogenic properties of growth factors and effectors, including angiopoietin, CXCL8, and MMP9, have been demonstrated in previous studies involving neutralization of antibodies, specific antagonists, or genetic disruption against specific factors [43–47]. In addition, one independent study demonstrated that EPCs may exhibit cytoprotective effects through the broad synergistic action of many growth factors and effectors, resulting from modulation of intracellular anti-oxidative defensive mechanisms and prosurvival signals [48]. In this study, both direct endothelial replacement with iEPCs and iEPCs' stimulation of the production of many proangiogenic growth factors and effectors were observed in AKI kidneys, and these effects contributed to the attenuation of microvascular rarefaction and tubular decomposition.

Our echocardiography data indicated that iEPC therapy exhibited a protective effect against AKI-induced cardiac dysfunction. We did not observe any GFP-iEPCs in mouse hearts, suggesting that the possibility of a direct cardiac effect was negligible. Considering that iEPC therapy prevented kidney injury, the protective effect of iEPC therapy on the heart may have resulted from the reduction of uremic toxin IS and proinflammatory IL-1β in circulation. Our study further supported that IS and IL-1β at the concentrations observed in patients with AKI were proapoptotic to cardiomyocytes. The number of apoptotic cardiomyocytes in AKI mice decreased after iEPC therapy, suggesting that iEPC therapy exerted prosurvival and anti-apoptotic effects resulting from the attenuation of AKI and the reduction of circulating IS and IL-1β levels. A recent study demonstrated that AKI may activate Drp1, inducing mitochondrial fragmentation and apoptosis in cardiomyocytes, but the mechanism underlying Drp1 activation and apoptosis in cardiomyocytes following renal I/R injury has not been identified [10]. In the present study, IS and IL-1β did not induce Drp1 activation, but our data supported that IS and IL-1β could induce apoptosis in cardiomyocytes, and this mechanism may account for cardiac dysfunction induced by AKI.

iPS cell technology enables the reprogramming of a wide variety of somatic cell types into various other types of cells. This technology offers a novel strategy for patient-specific...
derivation of clinically applicable lineage-specific cells, such as EPCs [15, 16, 49]. Directing the in vitro differentiation of iPS cells into functional EPCs may serve as a paradigm for human disease modeling and EPC-based therapies [15, 39, 40]. In the present study, iPS cells were differentiated into iEPCs, which expressed mature EPC markers such as CD133 and KDR. Thus, iPS cells can be used to derive numerous cells that can be differentiated into EPCs for transplantation purposes, as shown in this study. Moreover, recent evidence has revealed that iPS cells can also be induced to cells expressing markers of proximal tubules or podocytes [50–52]. Similar to the direct endothelial replacement by iEPCs in our study, Sharmin et al. demonstrated that the transplantation of human iPS cell-derived nephron progenitors, using spacers to release the tension of host kidney capsules, allowed the effective formation of glomeruli, in which iPS cell-derived podocytes accumulated around the fenestrated endothelial cells [52].

Tumorigenesis is a challenge in stem cell therapy. In some animal studies, direct implantation of iPS cells led to tumor formation [26, 53]. Therefore, directed differentiation into iEPCs should be conducted before transplantation to avoid the possibility of tumorigenesis. In this short-term study, we did not observe any abnormal cell proliferation after iEPC therapy. The long-term safety of iEPC therapy requires further exploration. Our data indicated that intravenous infusion of iEPCs did not cause abnormal proliferation in the heart or kidney (data not shown).

**Fig. 7** Systemic human iPS cell-derived iEPC therapy attenuated apoptosis of cardiomyocytes in acute kidney injury (AKI) mice. 

**a** Representative immunofluorescence images depicting TUNEL+ cells in the left ventricles on day 2 after sham or AKI. Arrows indicate TUNEL+ (green) nuclei (blue) and cardiomyocytes staining. Scale bar = 100 μm. 

**b** Bar chart illustrating quantitative analyses of TUNEL+ apoptotic cells per high-power field (×200 magnification) in the left ventricle on day 2 after sham or AKI. N = 8 per group. 

**c, d** Representative images of Western blot analyses of caspase 3 and Bcl-2 in the left ventricles on day 2 after sham or AKI. GAPDH was used as the control of protein loading. Bar charts illustrating quantitative analyses. N = 3 per group. Data are presented as mean ± SEM. *P < 0.05 AKI-V vs. Sham, #P < 0.05 AKI-iEPC vs. AKI-V group.
Conclusions
The present report demonstrated the potential of human iPS cell-derived iEPCs as a novel therapy for ischemic AKI and remote cardiac dysfunction. The protective effects of this therapy most likely result from attenuation of apoptosis and inflammation. Further research is required to verify the long-term safety of this therapy.

Additional file

**Additional file 1:** Figure S1. Characterization of human iPS cell-derived endothelial progenitor cells (iEPCs). Figure S2 Characterization of human iPS cell-derived endothelial progenitor cells (iEPCs). Figure S3 GFP-iEPC sorting. Representative flow cytometric analyses for (A) control iPS cells and (B) lentivirus-GFP-transduced iPS (GFP-iPS) cells. Figure S4 Gross appearance of kidneys with sham or AKI. Figure S5 Measurement of human angiogenesis-related proteins in the plasma of AKI mice. Figure S6 Increased plasma levels of brain natriuretic peptide in AKI patients. (DOC 7402 kb)

Abbreviations
AKI: Acute kidney injury; Angpt: Angiopoietin; BNP: Brain natriuretic peptide; CO: Cardiac output; FGF: Fibroblast growth factor; I/R: Ischemia–reperfusion; IGFBP: Insulin-like growth factor-binding protein; LVEF: Left ventricular ejection fraction; LVFS: Left ventricular fractional shortening; MMP9: Matrix metallopeptidase 9; TGF-β1: Transforming growth factor-β1; VEGF-C: Vascular endothelial cell growth factor-C

Acknowledgements
We would like to thank the Department of Medical Research of National Taiwan University Hospital for equipment support, the Imaging Core Facility of the First Core Laboratory, the Laboratory Animal Center of National Taiwan University College of Medicine, and the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica for the provision of EGFP lentivirus (C6-4-2).

Funding
WCS was supported by the Ministry of Science and Technology (MOST), Taiwan (102-2811-B-002-124, 103-2811-B-002-040, 104-2811-B-002-046). YHC was supported by MOST (104-2314-B-002-119-MY3) and the Mrs. Hsiu-Chin Lee Kidney Research Foundation.

Availability of data and materials
For data requests, please contact the author.

Authors’ contributions
The study was conceived by WCS, YHC, and HFC. WCS, YHC, HPH, and JFS were all involved in the performance of key experiments. WCS, YHC, and HFC performed data analysis. WCS wrote the first draft of the manuscript and performed experiments for revision with support from SCH. All authors
including SCH subsequently provided revisions to develop the final version of the manuscript for submission.

Ethics approval and consent to participate
This study was performed in compliance with the declaration of Helsinki and was approved by the Institutional Review Board of National Taiwan University Hospital, Taipei, Taiwan (2011110129B and 20090756R). All participants or their legal representatives provided written informed consent.

Consent for publication
Not applicable for consent for publication, because no individuals’ data were reported (including individual details, images, or videos) in this study.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1. Drug Development Center, Institute of New Drug Development, Institute of Biomedical Sciences, China Medical University, Taichung 404, Taiwan.
2. Graduate Institute of Physiology, National Taiwan University College of Medicine, Taipei, Taiwan. 3. Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 4. Renal Division, Department of Internal Medicine, National Taiwan University Hospital, Jinn-Shan Branch, New Taipei City, Taiwan. 5. Graduate Institute of Medical Genomics and Proteomics, National Taiwan University College of Medicine, Taipei, Taiwan. 6. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. 7. Department of Biotechnology, National Formosa University, Yun-Lin, Taiwan. 8. Integrative Stem Cell Center, Department of Orthopaedics, China Medical University Hospital, Taichung 404, Taiwan. 9. Institute of Biomedical Sciences, Academia Sinica, Taipei 105, Taiwan. 10. Division of Reproductive Endocrinology and infertility, Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan.

Received: 8 July 2018 Revised: 31 October 2018 Accepted: 26 November 2018 Published online: 10 December 2018

References
1. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, et al. Acute kidney injury: an increasing global concern. Lancet. 2013;382:897–907.
2. Hsu C-Y, Chertow GM, McCulloch CE, Fan D, Ordonez JD, Go AS. Nonrecovery of kidney function and death after acute on chronic renal failure. Clin J Am Soc Nephrol. 2009;4:891–898.
3. Chou HY, Huang TM, Wu VC, Wang CY, Shiao CC, Lai CF, et al. Impact of timing of renal replacement therapy initiation on outcome of septic acute kidney injury. Crit Care. 2011;15:R134.
4. Shiao CC, Ko WL, Wu VC, Huang TM, Lai CF, Lin YF, et al. U-curve association between timing of renal replacement therapy initiation and in-hospital mortality in postoperative acute kidney injury. PLoS One. 2012;7:e42952.
5. Wu V-C, Wu P-C, Wu C-H, Huang T-M, Chang C-H, Tsai P-R, et al. The impact of acute kidney injury on the long-term risk of stroke. J Am Heart Assoc. 2014;3(4).
6. Nath KA, Grande JP, Croat AJ, Frank E, Caplice NM, Hebbel RP, et al. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol. 2005;166:4963–72.
7. Grams ME, Rabb H. The distant organ effects of acute kidney injury. Kidney Int. 2012;81:10492–8.
8. Ahuja N, Andres-Hernando A, Altmann C, Bhargava R, Bacalja J, Webb KG, et al. Circulating IL-6 mediates lung injury via CXCL1 production after acute kidney injury in mice. Am J Physiol Ren Physiol. 2012;303:F686–F72.
9. Andres-Hernando A, Altmann C, Bhargava R, Okumura K, Bacalja J, Hunter B, et al. Prolonged acute kidney injury exacerbates lung inflammation at 7 days post acute kidney injury. Physiological Rep. 2014;2:7:e012084.
10. Sumida M, Doi K, Ogawa S, Yamashita T, Hamaoka Y, Kiyata T, et al. Regulation of mitochondrial dynamics by dynamin-related protein-1 in acute cardioeal syndrome. J Am Soc Nephrol. 2015;26:102378–87.
11. Li B, Cohen A, Hudson TE, Routt D, Armani DL, Duffield JS. Mobilized human hematopoietic stem/progenitor cells promote kidney repair after ischemia-reperfusion injury. Circulation. 2010;121:20221–20.
12. Xing L, Cui R, Peng L, Ma J, Chen X, Xie R-J, et al. Mesenchymal stem cells, not conditioned medium, contribute to kidney repair after ischemia-reperfusion injury. Stem Cell Res Ther. 2013;4:51–12.
13. Chou YH, Pan SY, Yang CH, Lin SL. Stem cells and kidney regeneration. J Formos Med Assoc. 2014;113:201–9.
14. Choi KD, Yu J, Smuga-Otto K, Salvagio G, Rehauer W, Vodyanik M, et al. Hematopoietic and endothelial differentiation of human induced pluripotent stem cells. Stem Cells. 2009;27:559–67.
15. Rufaihah A1, Huang NF, Jame S, Lee JC, Nguyen LN, Byers B, et al. Endothelial cells derived from human iPSCs increase capillary density and improve perfusion in a mouse model of peripheral arterial disease. Antierioscler Thromb Vasc Biol. 2011;31:1172–9.
16. Takahashi K, Tanabe K, Ohnuki M, Naita M, Ichisaka T, Torda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.
17. Trujillo O, Miura K, Okada Y, Fujiyoshi K, Mukaino M, Nagoshi N, et al. Therapeutic potential of appropriately evaluated self-induced pluripotent stem cells for spinal cord injury. Proc Natl Acad Sci. 2010;107:12704–9.
18. Toyohara T, Mae SI, Suetu SI, Inoue T, Yamagishi Y, Kawamoto T, et al. Cell therapy using human induced pluripotent stem cell-derived renal progenitors ameliorates acute kidney injury in mice. Stem Cells Transl Med. 2013;2:980–92.
19. Alev C, Il M, Asahara T. Endothelial progenitor cells: a novel tool for the therapy of ischemic disease. Antioxid Redox Signal. 2011;15:594–65.
20. Shen WC, Liang CJ, Wu VC, Wang SH, Young GH, Lai IR, et al. Endothelial progenitor cells derived from Wharton’s jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1alpha/IL-8 expression. Stem Cells Dev. 2013;22:1408–18.
21. Liang CJ, Shen WC, Chang FB, Wu VC, Wang SH, Young GH, et al. Endothelial progenitor cells derived from Wharton’s jelly of human umbilical cord attenuate ischemic acute kidney injury by increasing vascularization and decreasing apoptosis, inflammation, and fibrosis. Cell Transplant. 2015;24:363–77.
22. O’Neill AC, Ricardo SD. Human kidney cell reprogramming: applications for disease modeling and personalized medicine. J Am Soc Nephrol. 2013;24:1347–56.
23. Shen WC, Chou YH, Lin SL. Enthusiasm for induced pluripotent stem cell-based therapies in kidney regeneration. J Formos Med Assoc. 2016;115:3–9.
24. Huangfu D, Osafune K, Maehr R, Guo W, Eijikelenboom A, Chen S, et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2. Nat Biotechnol. 2008;26:1129–75.
25. Lee PY, Chen Y, Chou GH, Lin GH, Chou CH, Tang DC. Induced pluripotent stem cells without c-Myc attenuate acute kidney injury via downregulating the signaling of oxidative stress and inflammation in ischemia-reperfusion rats. Cell Transplant. 2012;21:2569–85.
26. Kawai H, Yamashita T, Ohya D, Deguchi K, Nagotani S, Zhang X, et al. Tridermal tumorigenesis of induced pluripotent stem cells transplanted in ischemic brain. J Cerub Blood Flow Metab. 2010;30:81489–93.
27. Yoo CH, Na HJ, Lee DS, Heo SC, An Y, Cha J, et al. Endothelial progenitor cells from human dental pulp-derived iPSCs as a therapeutic target for ischemic vascular diseases. Biomaterials. 2013;34:33149–60.
28. Kim HY, Yoo TH, Hwang Y, Lee GH, Kim GB, Jung J, et al. Indoxyl sulfate (iS)-mediated immune dysfunction provokes endothelial damage in patients with end-stage renal disease (ESRD). Sci Rep. 2017;7:3057.
29. Frangogiannis NG. Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiological and translational concepts. Discoveries (Croatia). 2015;3(1).
30. de Cairestecker M, Humphreys BD, Liu KD, Fissell WH, Cerda J, Nolin TD, et al. Bridging translation by improving preclinical study design in AKI. J Am Soc Nephrol. 2015;26:2905–16.
31. Kawamoto A, Gwon H-C, Iwaguro H, Yamaguchi J-I, Uchida S, Masuda H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation. 2001;103:634–7.
32. Ghaly T, Rabadi MM, Weber M, Rabadi SM, Bank M, Grom JM, et al. Hydrogel-embedded endothelial progenitor cells evade LPS and mitigate endotoxemia. Am J Physiol Ren Physiol. 2011;301:F802–F12.
33. Patschan D, Krupincza K, Patschan S, Zhang Z, Hambly C, Golgosky MS. Dynamics of mobilization and homing of endothelial progenitor cells after acute renal ischemia: modulation by ischemic preconditioning. Am J Physiol Ren Physiol. 2006;291:F76–F85.
34. Hohenstein B, Kuo M-C, Addabbo F, Yasuda K, Ratiff B, Schwarzenberger C, et al. Enhanced progenitor cell recruitment and endothelial repair after selective endothelial injury of the mouse kidney. Am J Physiol Ren Physiol. 2010;298:F1504–F14.

35. Wu Y-C, Young G-H, Huang P-H, Lo S-C, Wang K-C, Sun C-Y, et al. Acute kidney injury, indoxyl sulfate repairs human endothelial progenitor cells: modulation by statin. Angiogenesis. 2013;16:609–24.

36. Aturi P, Trubelja A, Fairman AS, Hsiao P, MacArthur JW, Cohen JE, et al. Normalization of postinfarct biomechanics using a novel tissue-engineered angiogenic construct. Circulation. 2013;128(1 Suppl):S95–S104.

37. Masuda H, Tanaka R, Fujisma R, Ishihara S, Aikamur H, Shizuno T, et al. Vascularogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential. J Am Heart Assoc. 2014;3:e000743.

38. Nelson J, Wu Y, Jiang X, Berretta R, Houser S, Choi E, et al. Hyperhomocysteinemia suppresses bone marrow CD34+/VEGF receptor 2+ cells and inhibits progenitor cell mobilization and homing to injured vasculature—a role of β3-integrin in progenitor cell migration and adhesion. FASEB J. 2015;29:3085–99.

39. Hirota K, Zemeck H, Bidzhekov K, Liehn EA, Shagdarsuren E, Ludwig A, et al. Importance of CXC chemokine receptor 2 in the homing of human peripheral blood endothelial progenitor cells to sites of arterial injury. Circ Res. 2007;100:93–97.

40. Giordano S, Zhao X, Ding D, Hage F, Oparil S, Cooke JP, et al. Targeted delivery of human iPS-ECs overexpressing IL-8 receptors inhibits neointimal and inflammatory responses to vascular injury in the rat. Am J Physiol Heart Circ Physiol. 2016;310:H705–H15.

41. Rehman J, Li J, Orschell CM, March KL. Peripheral blood “endothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164–9.

42. Zarjou A, Kim J, Traylor AM, Sanders PW, Balla J, Agarwal A, et al. Paracrine effects of mesenchymal stem cells in cisplatin-induced renal injury require heme oxygenase-1. Am J Physiol Ren Physiol. 2011;300:F154–F62.

43. Tressel SL, Kim H, Ni CW, Chang K, Velasquez-Gastano JC, Taylor WR, Yoon YS, Jo H. Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscler Thromb Vasc Biol. 2008;28:1989–95.

44. Kanayasu-Toyoda TTT, Kikuchi Y, Uchida Y, Matsuyama Y, Yamaguchi T. Cell-surface MMP-9 protein is a novel functional marker to identify and separate pro-angiogenic cells from early endothelial progenitor cells derived from adult blood. Stem Cells. 2013;31:1251–62.

45. Santo SDFA, Periasamy R, Seiler S, Widmer HR. The cytoprotective effects of human endothelial progenitor cells-conditioned medium against an ischemic insult are VEGF and IL-8 dispensable. Cell Transplant. 2016;25:735–47.

46. Qh T, Zeng H, Sinnett A, Yu H, Aschner JL, Liao DF, et al. Critical role of angiopoietin/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis. Am J Physiol Heart Circ Physiol. 2008;294:H2547–H57.

47. Shen WC, Wu VC, Wang SH, Young GH, Lai IR, Chien CL, Wang SM, Wu KD, Chen YL. Endothelial progenitor cells derived from Wharton’s jelly of the umbilical cord reduces ischemia-induced hind limb injury in diabetic mice by inducing HIF-1α/IL-8 expression. Stem Cells Dev. 2013;22:1408–18.

48. Yang Z, von Ballmoos MW, Faessler D, Voelzmann J, Ortman J, Diehm N, Kalka-Moll W, Baumgartner I, Di Santo S, Kalka C. Paracrine factors secreted by inducing hif-1α/IL-8 expression. Stem Cells Dev. 2013;22:1408–18.

49. Park SW, Jun KJ, Yoon Jeon J, Cho YH, Jang MJ, Kang Y, et al. Efficient differentiation of human pluripotent stem cells into functional CD34+ progenitor cells by combined modulation of the MEK/ERK and BMP4 signaling pathways. Blood. 2010;116:5762–72.

50. Mae S, Shono A, Shiota F, Yasuno Y, Kajiwara M, Gotoya-Nishimura N, et al. Monitoring and robust induction of nephrogenic intermediate mesoderm from human pluripotent stem cells. Nat Commun. 2013;4:1367.

51. Lam AQ, Freedman BS, Morizane R, Lerou PH, Valerius MT, Bonventre JV. Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing proximal tubular markers. J Am Soc Nephrol. 2014;25:1211–21.

52. Shimizu S, Taguchi Y, Kikunari T, Shimizu M, Araki T, Sakuma T, et al. Human induced pluripotent stem cell-derived podocytes mature into vasculared glomerul on experimental transplantation. J Am Soc Nephrol. 2016;5:1778–91.

53. Yamamoto M, Cui L, Yohuka K, Asanuma K, Okouchi Y, Ogawa N, et al. Branching ducts similar to mesonephric ducts or ureteric buds in teratomas originating from mouse embryonic stem cells. Am J Physiol Ren Physiol. 2006;290:F52–60.